Pyxis Oncology, Inc. — All Filings
318 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-K/A
10-Q
144
144/A
3
4
424B2
424B3
424B4
425
8-A12B
8-K
8-K/A
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
POS AM
PRE 14A
S-1
S-1/A
S-1MEF
S-3
S-4
S-4/A
S-8
S-8 POS
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| SC 13G | PYXIS ONCOLOGY, INC. | 0000902664-22-001604 | Feb 14, 2022 | — |
| SC 13G/A | SC 13G/A | 0001104659-22-022766 | Feb 14, 2022 | — |
| SC 13G | SC 13G | 0001104659-22-020578 | Feb 11, 2022 | — |
| SC 13G | THE SCHEDULE 13G | 0000921895-21-002880 | Dec 20, 2021 | — |
| 4 | FORM 4 SUBMISSION | 0000899243-21-047525 | Dec 9, 2021 | Dec 8, 2021 |
| 4 | FORM 4 SUBMISSION | 0000899243-21-047102 | Dec 7, 2021 | Dec 6, 2021 |
| 4 | FORM 4 SUBMISSION | 0000899243-21-045363 | Nov 19, 2021 | Nov 18, 2021 |
| 10-Q | 10-Q | 0000950170-21-004476 | Nov 15, 2021 | Sep 30, 2021 |
| 8-K | 8-K | 0000950170-21-004462 | Nov 15, 2021 | — |
| SC 13G | SC 13G | 0001104659-21-129526 | Oct 25, 2021 | — |
| S-8 | S-8 | 0001193125-21-305462 | Oct 22, 2021 | — |
| SC 13D | — | 0000905148-21-000683 | Oct 22, 2021 | — |
| 4 | FORM 4 | 0001567619-21-018355 | Oct 15, 2021 | Oct 13, 2021 |
| 4 | PRIMARY DOCUMENT | 0001578563-21-000038 | Oct 15, 2021 | Oct 13, 2021 |
| 4 | FORM 4 | 0001140361-21-034643 | Oct 15, 2021 | Oct 13, 2021 |
| 4 | FORM 4 | 0001140361-21-034645 | Oct 15, 2021 | Oct 13, 2021 |
| 4 | FORM 4 | 0001140361-21-034425 | Oct 12, 2021 | Oct 7, 2021 |
| 4 | FORM 4 | 0001140361-21-034427 | Oct 12, 2021 | Oct 7, 2021 |
| 4 | FORM 4 | 0001140361-21-034426 | Oct 12, 2021 | Oct 7, 2021 |
| 4 | FORM 4 | 0001140361-21-034424 | Oct 12, 2021 | Oct 7, 2021 |
| 4 | FORM 4 | 0001140361-21-034423 | Oct 12, 2021 | Oct 7, 2021 |
| 4 | FORM 4 | 0001140361-21-034422 | Oct 12, 2021 | Oct 7, 2021 |
| 4 | FORM 4 | 0001140361-21-034421 | Oct 12, 2021 | Oct 7, 2021 |
| 4 | FORM 4 | 0001140361-21-034420 | Oct 12, 2021 | Oct 7, 2021 |
| 4 | FORM 4 | 0001140361-21-034419 | Oct 12, 2021 | Oct 7, 2021 |
| 424B4 | 424B4 | 0001193125-21-295600 | Oct 8, 2021 | — |
| 3 | FORM 3 | 0001140361-21-034070 | Oct 7, 2021 | — |
| EFFECT | — | 9999999995-21-003820 | Oct 7, 2021 | — |
| S-1MEF | S-1MEF | 0001193125-21-294497 | Oct 7, 2021 | — |
| 3 | FORM 3 | 0001140361-21-034083 | Oct 7, 2021 | — |
| 3 | FORM 3 | 0001140361-21-034081 | Oct 7, 2021 | — |
| 3 | FORM 3 | 0001140361-21-034079 | Oct 7, 2021 | — |
| 3 | FORM 3 | 0001140361-21-034077 | Oct 7, 2021 | — |
| 3 | PRIMARY DOCUMENT | 0001578563-21-000036 | Oct 7, 2021 | — |
| 3 | FORM 3 | 0001140361-21-034075 | Oct 7, 2021 | — |
| 3 | FORM 3 | 0001140361-21-034072 | Oct 7, 2021 | — |
| 3 | FORM 3 | 0001140361-21-034068 | Oct 7, 2021 | — |
| 3 | FORM 3 | 0001140361-21-034066 | Oct 7, 2021 | — |
| 3 | FORM 3 | 0001140361-21-034063 | Oct 7, 2021 | — |
| SEC STAFF LETTER | — | 9999999997-21-005189 | Oct 7, 2021 | — |
| 3 | FORM 3 | 0001567619-21-018043 | Oct 7, 2021 | — |
| S-1/A | S-1/A | 0001193125-21-293655 | Oct 7, 2021 | — |
| CERT | — | 0001354457-21-001130 | Oct 6, 2021 | — |
| CORRESP | — | 0001193125-21-292052 | Oct 5, 2021 | — |
| CORRESP | — | 0001193125-21-292066 | Oct 5, 2021 | — |
| 8-A12B | 8-A12B | 0001193125-21-292187 | Oct 5, 2021 | — |
| S-1/A | S-1/A | 0001193125-21-290298 | Oct 4, 2021 | — |
| S-1/A | S-1/A | 0001193125-21-288350 | Oct 1, 2021 | — |
| CORRESP | — | 0001193125-21-285776 | Sep 28, 2021 | — |
| SEC STAFF LETTER | — | 9999999997-21-004807 | Sep 17, 2021 | — |